2016 Cohen Veterans Care Summit Highlights

The inaugural Cohen Veterans Care Summit focused on advancements in bioscience and precision medicine to advance the PTSD & TBI research roadmap through public-private partnerships.
World-class brain health experts and leaders from across government, academia, industry and non-profit organizations shared the latest developments in biomarkers, diagnostics, translational models, genetics, biosensors and mobile health for PTSD and TBI.

The Summit was jointly hosted by Cohen Veterans Bioscience and Cohen Veterans Network, both leading national non-profit organizations funded by financier-philanthropist Steven A. Cohen to advance the state of Post Traumatic Stress (PTS) & Traumatic Brain Injury (TBI) care today and tomorrow.

This year’s inaugural meeting focused on advancements in bioscience and precision medicine, including opportunities for advancing the PTSD & TBI research roadmap through public-private partnerships.

Participants in this invitation-only event included leaders from academia, Department of Defense, National Institutes of Health, Veterans Administration, foundations and industry.

By Joining Forces with partners from all sectors, we can accelerate the Veterans Mental Health agenda for Veterans, Service members and all individuals affected by PTS & TBI.

Opening Remarks by Magali Haas, MD, PhD, at the 2016 Cohen Veterans Care Summit

 Watch the 2016 Cohen Veterans Care Summit Highlights Video

Highlights from the Cohen Veterans Care Summit

  • Financier-Philanthropist Steven A. Cohen and Cohen Veterans Bioscience President & CEO Dr. Magali Haas welcomed attendees with calls to advance the PTSD and TBI research agenda in the face of an invisible epidemic, noting that more than a million service members and veterans, and more than 9 million civilians, have been diagnosed with these conditions. Mr. Cohen has committed more than $300 million to support Cohen Veterans Network and Cohen Veterans Bioscience.

    care-summit-shulkin

    VA Under Secretary for Health Dr. David Shulkin

  • VA Under Secretary for Health Dr. David Shulkin, FDA Commissioner Robert Califf, and Jonathan Woodson, Faculty Director of the Institute for Health System Innovation at Boston University, emphasized the necessity for collaboration and innovation. Dr. Shulkin reported strides in suicide prevention, improved access to mental health care, and recent adoption of innovative solutions to treating veterans at the VA. Dr. Califf emphasized the importance of developing biomarkers for PTSD and TBI so that we can measure the benefits from treatments, and predicted that technological advancements like wearable biosensors will soon lead to exciting new diagnostic devices. Dr. Woodson highlighted the need to institute smart policies in parallel with advancing medical research.
  • As a combat veteran who served in Afghanistan and Iraq, Garret Combs shared his own experience of PTSD and delivered an unexpected message: “Don’t thank me for my service,” he said, because putting vets on a pedestal only intensifies feelings of difference, isolation and an inability to relate to one’s community.
  • Cohen Veterans Network President and CEO Dr. Anthony Hassan reported overwhelming demand for services at the five clinics the organization has opened so far, and projected that eventually there would be 20 or more sites around the US. CVN provides mental health care to veterans and their families at no charge, regardless of discharge status.care-summit-am-panel3
  • A wide-reaching federal plan to improve access to mental health services for veterans, service members, and military families is moving forward. The National Research Action Plan (NRAP), established in 2013, is building collaborations to standardize, integrate, and share data as appropriate, build new tools and technologies, and work to maximize the impact of research findings.
  • PTSD goes back 3,000 years, said Dr. Charles Marmar of New York University. The earliest PTSD-like case in medical history was a Syrian soldier who lived in 1300 B.C. Similar conditions have been recognized repeatedly over the centuries, usually after a war and called by names like “soldier’s heart,” “battle fatigue,” and “shell shock.” But the symptoms have remained consistent — nightmares, memory problems, insomnia, withdrawal.
  • Women’s higher rate of PTSD may be due in part to sex-related differences in how their brains respond to trauma, said Dr. Eric Kandel, Nobel Laureate and professor at Columbia University. In a mouse model of conditioned fear, female — but not male — mice without the TIA-1 gene exhibit stress-induced PTSD-like phenotypes. In contrast, increasing TIA-1 aggregation enhances its protective function, leading to a reduction in fear-related behaviors.

    care-summit-kandel3

    Nobel Laureate Dr. Eric Kandel

  • We understand cancer much better than neurodegeneration because we know why cells proliferate, but we really don’t know why they die. To make progress in TBI and related diseases, said Dr. Kenneth Kosik of UC Santa Barbara, we need to better understand how misfolded versions of proteins like tau, which is involved in TBI, escape cellular degradation.
  • Wearable devices will soon provide medical-grade data for research and treatment of PTSD and other conditions. Ruben de Francisco of the nanoelectronic research institute Imec demonstrated an electrode-studded cap, wristband, and skin patch that can collect data on heart and brain activity, skin conductance, physical activity and other factors.
  • Fear is a natural response — and one critical for the survival of an organism. PTSD is thought to arise from changes in how the brain processes fear and fear-related behaviors. A number of models have been developed to explore neural circuits that underlie PTSD symptoms. Dr. Israel Liberzon of the University of Michigan argued that the brain’s capacity to put fears in context — its ability to react differently to a lion in the zoo and a lion in your backyard — is key to understanding PTSD.
  • Numbers are key to identifying genes associated with neuropsychiatric conditions. Early efforts by the Psychiatric Genomics Consortium (PGC) to identify genetic risk factors underlying schizophrenia failed for one simple reason, said Dr. Karestan Koenen of the Harvard School of Public Health — sample size. It took 9,000 patients to find a genetic variant in the MHC gene that contributes to increased schizophrenia risk. In PTSD, a partnership between Cohen Veterans Bioscience and PGC expects to have 25,000 cases analyzed by the end of 2016.
  • Veterans aren’t getting the care they deserve, despite the tireless efforts of advocates, Cohen Veterans Bioscience Board Secretary Theresa Frangiosa said in opening day two of the Summit. One way to move forward, said Board Member Michael Sullivan, is through coordination between Cohen Veterans Bioscience and Cohen Veterans Network that realizes financier-philanthropist Steven A. Cohen’s vision of translating groundbreaking research to the clinic.
  • Admiral Brian Losey emphasized the importance of continuous care and monitoring of military personnel over their careers. The idea is not just to prevent or treat PTSD in individuals – but to enhance, measure and reinforce institutional resiliency. Like any combat injury, PTSD compromises talented service members’ capacity to move up through the ranks and shape the future of the armed forces.
  • care-summit-day-2-5

    Cohen Veterans Bioscience
    President & CEO Dr. Magali Haas

    The tough question she asked herself when starting Cohen Veterans Bioscience, Dr. Magali Haas reported, was “What can this organization bring to the table when billions of dollars are necessary to bring a single CNS drug to market?” Today, the resounding answer is that a patient-driven, nimble and flexible organization adds tremendous value. Embracing the core principles of imagination, integration and acceleration, Cohen Veterans Bioscience is positioned to investigate the biomarker landscape, improve the validity of animal models and harness the complexity of big data using computational modeling methods.

  • Pulling useful insights about PTSD from all the relevant scientific knowledge is like trying to book a flight using an unabridged map of the North American flight network, said David King, founder of Exaptive, Inc. His company is working on a PTSD KnowledgeMap™ that helps researchers see meaningful connections between data points much the way online travel sites help people find a flight.
  • care-summit-day-2-pkPromising results in preclinical studies often fail in human testing due to the lack of validity in animal models. Our AMP IT UP initiative is trying to bridge that gap by developing preclinical models that more accurately reflect PTSD. However, as Dr. Kerry Ressler of Harvard Medical School points out, the goal is not to make a “PTSD mouse” but to model relevant processes that are known to occur in both species.
  • There are over 630,000 ways to reach a PTSD diagnosis using the DSM-V. But this complexity does have a silver lining, said Dr. Amit Etkin of Stanford University. It gives us the opportunity to rethink how we define this disease. He presented research showing there is a subset of PTSD patients who tend not to benefit from prolonged exposure therapy. But data from various sources raises the possibility that transcranial magnetic stimulation (TMS) might cause shifts in brain activity that could improve their response to that approach. He is working on the BEST-PTSD (Biomarker Establishment for Superior Treatment in PTSD) program – a new partnership with Cohen Veterans Bioscience – to help explore which patients will benefit from treatment in the real world.
  • Treatments like the TMS-psychotherapy combination that Dr. Etkin described will be challenging to develop. Several speakers noted that it is difficult enough to test drugs in preclinical animal models. Determining the effectiveness of multimodal therapies in ways that can be reliably translated to humans will be even more challenging, said Dr. Larry Hardy of Sunovion Pharmaceuticals.
  • Like Alzheimer’s Disease, Traumatic Brain Injury (TBI) is a tauopathy, one of many conditions that involves the accumulation of tau protein in the brain. Tau is currently sampled from cerebrospinal fluid (CSF) or blood plasma, said Dr. Mony de Leon of New York University. However, there may be a better way: recent research shows that CSF leaks out of the brain’s olfactory bulb into the deep recesses of the nose.
  • Only 26 studies of PTSD have been published in the last 60 years that use post-mortem tissue, compared with 4,500 studies of Alzheimer’s Disease. The Cohen Brain Collection – a collaboration between Cohen Veterans Bioscience and the Harvard Brain Tissue Research Center – aims to fill that gap by collecting high-quality brain specimens. To truly understand PTSD, said HBTRC co-director Dr. Sabina Berretta, we must look closely at the human brain – and post-mortem tissue is our only way of accessing this critical organ. As Dr. Berretta concluded, “The gift of a brain is a gift of knowledge.”

2016 Cohen Veterans Care Summit Speakers

  • Patrick SF Bellgowan, PhD
    Patrick SF Bellgowan, PhD Program Director for TBI Research
    National Institute for Neurological Disorders and Stroke (NINDS)

    Patrick SF Bellgowan, PhD

    Program Director for Traumatic Brain Injury Research
    National Institute for Neurological Disorders and Stroke (NINDS)
    Patrick Bellgowan, PhD, is currently the Program Director for traumatic brain injury (TBI) research at the National Institute for Neurological Disorders and Stroke (NINDS). The NINDS TBI portfolio covers a broad spectrum of research from disease-related basic research to large clinical research programs. In addition to overseeing the TBI portfolio for NINDS, he is also programmatically involved in NIH’s Brain Initiative, Human Connectome project, the NIH Common funds Big Data to Knowledge program, serves on several Interagency steering committees, and is co-director of the Federal Interagency TBI Research effort. Patrick received his PhD at the University of Wisconsin-Milwaukee in behavioral neuroscience studying the role of amygdala in fear conditioning. He did his postdoctoral training investigating medial temporal lobe function using functional neuroimaging at the Medical College of Wisconsin and later in the Intramural program at NIH. Before coming to the extramural program at NINDS, he was the Director of Cognitive Neuroscience and Associate Professor at the Laureate Institute for Brain Research and University of Tulsa, where he used magnetic resonance neuroimaging and immunological methods to study the acute effects of concussion in college athletes.

    close
    View Bio
  • Sabina Berretta, MD
    Sabina Berretta, MD Associate Professor of Psychiatry
    Harvard Medical School

    Sabina Berretta, MD

    Associate Professor of Psychiatry
    Harvard Medical School

    Sabina Berretta, MD, is an Associate Professor of Psychiatry at Harvard Medical School, and Director of the Translational Neuroscience Laboratory and Scientific Director of the Harvard Brain Tissue Resource Center (HBTRC), both at McLean Hospital, Harvard Medical School. She earned her medical degree at the Facolta’ di Medicina e Chirurgia, Catania University, Italy, and trained with Dr. Ann M. Graybiel, Department of Brain and Cognitive Sciences, MIT, and with Dr. Francine Benes, at McLean Hospital.

    Sabina and her research team at the Translational Neuroscience Laboratory conduct investigations on the pathophysiology of psychiatric disorders. Specifically, human postmortem, in vitro, and animal model studies are used to investigate the role of the brain extracellular matrix in normal and pathological states. Current studies are aimed at testing hypotheses on abnormalities in molecular composition of the brain extracellular matrix organized structures and cell populations affected by these abnormalities.

    Sabina also co-directs the HBTRC, a tissue repository currently funded by the NIH to collect brain samples from donors with a variety of brain disorders as well as healthy controls. The HBTRC also houses the Cohen Brain Collection, dedicated to collecting brain samples from donors with PTSD or TBI.

    close
    View Bio
  • Daniela Brunner, PhD
    Daniela Brunner, PhD Founder and President
    Early Signal Foundation

    Daniela Brunner, PhD

    Founder and President
    Early Signal Foundation

    Daniela Brunner, PhD, is the founder and President of Early Signal Foundation. She has worked in the analysis of models of developmental, psychiatric, and neurodegenerative disease models for the last 20 years. A major focus of her work has been establishing and automatizing rodent behavioral tests and novel high throughput preclinical platforms using computer vision and machine learning algorithms to comb behavioral signatures for phenotyping, drug screening, and systems biology approaches. As Senior Vice-President of Behavioral Research at PsychoGenics, she was in charge of large projects focused on back-translation of anti-smoking cessation medication, preclinical cognitive assessment, and studies in neurodegeneration, psychiatry, and autism. The current overarching goal of Daniela’s work is to establish analytical systems that integrate behavioral and “omics” readouts for the discovery of novel therapeutics. She aims to develop new tools for the analysis of health signatures in humans, particularly for rare disorders, with a special interest in connecting genomic information with behavioral domains, especially those passively captured with wearable sensors.

    close
    View Bio
  • Robert M. Califf, MD, MACC
    Robert M. Califf, MD, MACC Commissioner
    United States Food and Drug Administration

    Robert M. Califf, MD, MACC

    Commissioner
    United States Food and Drug Administration

    Robert M. Califf, MD, MACC, is the Food and Drug Administration’s commissioner of food and drugs. As the top official of the FDA, Dr. Califf is committed to strengthening programs and policies that enable the agency to carry out its mission to protect and promote the public health.

    Previously, Dr. Califf served as the FDA’s Deputy Commissioner for Medical Products and Tobacco from February 2015 until his appointment as commissioner in February 2016. In that capacity, he provided executive leadership to the Center for Drug Evaluation and Research, the Center for Biologics Evaluation and Research, the Center for Devices and Radiological Health, and the Center for Tobacco Products. He also oversaw the Office of Special Medical Programs and provided direction for cross-cutting clinical, scientific, and regulatory initiatives, including precision medicine, combination products, orphan drugs, pediatric therapeutics, and the advisory committee system.

    Prior to joining the FDA, Dr. Califf was a professor of medicine and vice chancellor for clinical and translational research at Duke University. He also served as director of the Duke Translational Medicine Institute and founding director of the Duke Clinical Research Institute. A nationally and internationally recognized expert in cardiovascular medicine, health outcomes research, healthcare quality, and clinical research, Dr. Califf has led many landmark clinical trials and is one of the most frequently cited authors in biomedical science, with more than 1,200 publications in the peer-reviewed literature.

    Dr. Califf has served on the Institute of Medicine (IOM) committees that recommended Medicare coverage of clinical trials and the removal of ephedra from the market, as well as on the IOM Committee on Identifying and Preventing Medication Errors and the IOM Health Sciences Policy Board. He has served as a member of the FDA Cardiorenal Advisory Panel and FDA Science Board’s Subcommittee on Science and Technology. Dr. Califf has also served on the Board of Scientific Counselors for the National Institutes of Health and the National Library of Medicine, as well as on advisory committees for the National Cancer Institute, the National Heart, Lung, and Blood Institute, the National Institute of Environmental Health Sciences and the Council of the National Institute on Aging.

    While at Duke, Dr. Califf led major initiatives aimed at improving methods and infrastructure for clinical research, including the Clinical Trials Transformation Initiative (CTTI), a public-private partnership co-founded by the FDA and Duke. He also served as the principal investigator for Duke’s Clinical and Translational Science Award and the NIH Health Care Systems Research Collaboratory coordinating center.

    Dr. Califf is a graduate of Duke University School of Medicine. He completed a residency in internal medicine at the University of California, San Francisco and a fellowship in cardiology at Duke.

    close
    View Bio
  • Steven A. Cohen, BS
    Steven A. Cohen, BS Chairman and CEO
    Point72 Asset Management

    Steven A. Cohen, BS

    Chairman and CEO
    Point72 Asset Management

    Steven A. Cohen is the Chairman and Chief Executive Officer of Point72 Asset Management, a 1,000-person family office managing the assets of Mr. Cohen and certain eligible employees. Mr. Cohen founded S.A.C. Capital Advisors in 1992 and converted his investment operations to the Point72 Asset Management family office in 2014. An avid philanthropist and entrepreneur, Mr. Cohen has founded and holds active leadership roles in a number of nonprofit organizations.

    Mr. Cohen is the Co-Chair and Founder of the Steven & Alexandra Cohen Foundation. Started in 2001 by Mr. Cohen and his wife Alexandra, the Steven & Alexandra Cohen Foundation is committed to achieving lasting and meaningful change through commitments to children’s health, education, veterans, and the arts. A longtime advocate for veterans with a particular interest in veterans’ mental health issues, Mr. Cohen co-founded Cohen Veterans Network and Cohen Veterans Bioscience in 2015 to improve the mental healthcare, treatment, and quality of life for recently-returned veterans and their families. He sits on the Board of Cohen Veterans Network.

    Mr. Cohen also serves on the Board of Trustees at the Museum of Contemporary Art (MOCA) in Los Angeles and the Emeritus Board of the Robin Hood Foundation. Mr. Cohen received a B.S. in Economics from The Wharton School at the University of Pennsylvania. He began his investing career at Gruntal & Co., where he managed proprietary capital for 14 years before starting his own investment business.

    close
    View Bio
  • Garrett Combs, BS
    Garrett Combs, BS Filmmaker & Media Producer

    Garrett Combs, BS

    Filmmaker & Media Producer

    Garrett Combs is a filmmaker, media producer, and thought contributor working to elevate understanding around veterans’ issues and push the boundaries of quality mental healthcare through authentic storytelling and new media. Garrett joined the Army in 2004, serving in Afghanistan and Iraq as a light infantry soldier before exiting the military in 2009 and earning his BS in Visual Communication. His experience transitioning back to civilian life contributes greatly to his desire to explore the topic of reintegration, as his unit has lost over 10 members to suicide, drug overdose, and other preventable deaths. Garrett’s story was chronicled in the CNN feature documentary The War Comes Home: Soledad O’Brien Reports. Garrett’s work has allowed him to intimately interview over 100 veterans about their time in war and coming home, giving him a rich understanding of this complex experience. Recently Garrett has been working on a collaborative multi-platform series for PBS called Veterans Coming Home, where he personally explores the topics of moral injury and soul loss. He believes that the mental health crisis among our veterans is much less a representation of the soldier’s experience in combat and far more a reflection of the society that sends that soldier to war.

    close
    View Bio
  • Paul Dagum, MD, PhD
    Paul Dagum, MD, PhD Founder
    Mindstrong

    Paul Dagum, MD, PhD

    Founder
    Mindstrong

    Head of Technology
    Elementum

    Paul Dagum, MD, PhD, is the founder of Mindstrong, an advisor to Health 2047, the American Medical Association’s innovations studio, and the Head of Technology at Elementum. He has managed global R&D teams with a track record of creating and launching products in three successful venture-backed companies as founder, VP Engineering, CTO, and CSO. He has delivered exceptional results through in-depth understanding of markets, implementation of successful R&D strategies, and development of strong teams. Paul has deep industry experience leading R&D in big data, machine learning, natural language processing, and informatics. Prior to his corporate career, he led National Science Foundation and NIH grants at Stanford University, published over 60 peer-reviewed articles and book chapters on computer science and medicine, and was awarded over 20 patents. He received an MSc in theoretical physics, a PhD in theoretical computer science (both from the University of Toronto), and an MD from Stanford University, where he also completed a postdoctoral research fellowship.

    close
    View Bio
  • Mony J. de Leon, EdD
    Mony J. de Leon, EdD Director of the Center for Brain Health and Professor of Psychiatry
    NYU School of Medicine

    Mony J. de Leon, EdD

    Director of the Center for Brain Health and Professor of Psychiatry
    NYU School of Medicine

    Mony J. de Leon, ED.D, is Director of the Center for Brain Health and Professor of Psychiatry at the NYU School of Medicine. He completed his doctoral work in Gerontology at Columbia University in 1980 followed by NIH-supported post-doctoral training in computed tomography brain imaging at NYU (psychiatry and radiology) and positron emission tomography (PET) imaging at the Brookhaven National Laboratory. He has over 400 publications dealing with the use of brain imaging and CSF biomarkers to improve the understanding of the pathophysiology of neurodegenerative diseases. Mony’s current work is focused on tau pathology in aging and traumatic brain injury (TBI). Additionally, he and his team recently invented a PET-based method for measuring the clearance of waste products from the human brain, of potential use in the study of TBI and dementia. In 2006, he was honored in Tubingen, Germany, as the “World’s Pioneer in Brain Imaging in Alzheimer’s Disease” at the 100th anniversary celebration of Alois Alzheimer’s first publication. In 2016, he was identified as a pioneer in the development of FDG-PET at the Society for Nuclear Medicine.

    close
    View Bio
  • Ruben de Francisco, PhD
    Ruben de Francisco, PhD Program Manager
    IMEC

    Ruben de Francisco, PhD

    Program Manager
    IMEC

    Ruben de Francisco, PhD, is Program Manager at IMEC, where he leads the activities on wearable healthcare. He is responsible for the development of complete solutions for wearable health applications, both for medical and consumer markets, including wearable devices, algorithms, data analytics, and integrated circuits, validated in real-life applications with our clinical and research partners. Ruben holds an electrical engineering degree from Polytechnic University of Catalonia (UPC), Barcelona, Spain, and a PhD in signal processing from Télécom ParisTech (ENST), Paris, France.

    close
    View Bio
  • Amit Etkin, MD, PhD
    Amit Etkin, MD, PhD Associate Professor of Psychiatry and Behavioral Sciences
    Stanford University

    Amit Etkin, MD, PhD

    Associate Professor, Psychiatry and Behavioral Sciences
    Stanford University

    Investigator
    VA Sierra-Pacific Mental Illness Research Education and Clinical Center (MIRECC) at the Palo Alto VA

    Amit Etkin, MD, PhD, is an Associate Professor in the Department of Psychiatry and Behavioral Sciences at Stanford University and at the Palo Alto VA. He is trained as both a neuroscientist and psychiatrist. The overarching aim of the Etkin Lab is to understand the neural basis of emotional disorders and their treatment, and to leverage this knowledge to better understand how the brain works and to develop novel treatment interventions. In support of this goal, he also co-directs a new initiative from the Stanford Neurosciences Institute called NeuroCircuit, which brings together neuroscientists, engineers, psychologists, physicians, and others to establish a new intellectual, scientific, and clinical paradigm for understanding and manipulating human brain circuits in healthy individuals and for treating psychiatric disease.

    close
    View Bio
  • Alan Evans, PhD
    Alan Evans, PhD James McGill Professor of Neurology and Psychiatry
    McGill University

    Alan Evans, PhD

    James McGill Professor of Neurology and Psychiatry
    McGill University

    Alan Evans, PhD, is a James McGill Professor of Neurology and Psychiatry at McGill University. He is a worldwide authority on brain mapping. His research interests include multi-modal brain imaging and network modeling (www.mcin.ca). He has 540 peer-reviewed publications. In 2003, he received a CIHR Senior Scientist award. In 2014, he received the Vezina Prize for Quebec Neuroradiology, the national Margolese Human Brain Disorders Prize, and recognition as a Highly Cited Scientist (top 1%) for Neuroscience and Behavior. Alan is a Fellow of the Royal Society of Canada and was elected Chair of the Organization for Human Brain Mapping (OHBM) in 2015. In 2016, he was awarded the Prix du Québec (Wilder Penfield). He co-directs the Ludmer Centre for Neuroinformatics and Mental Health, integrating imaging, behavior, and genetics in brain research. He heads a Canadian network in large-scale grid-processing (CBRAIN) and developed a popular web-based databasing technology (LORIS). He founded Biospective Inc., a Montreal-based, contract research organization specializing in pre-clinical and clinical imaging (MRI and PET) and neuropathology studies of diseases of the CNS (www.biospective.com).

    close
    View Bio
  • Lindsey Grandison, PhD
    Lindsey Grandison, PhD Program Officer
    National Institutes of Health (NIH) National Institute of Alcohol Abuse and Alcoholism (NIAAA)

    Lindsey Grandison, PhD

    Program Officer
    National Institutes of Health (NIH) National Institute of Alcohol Abuse and Alcoholism (NIAAA)

    Lindsey Grandison, PhD, is on the faculty in the Department of Physiology and Biophysics at the Robert Wood Johnson Medical School, and is a program officer at the National Institutes of Health (NIH) National Institute of Alcohol Abuse and Alcoholism (NIAAA). He received his PhD in physiology from Michigan State University. During his academic career, he was actively involved in neuroendocrine research investigating the role of hypothalamic mechanisms in regulation of anterior pituitary hormone secretion. This then evolved to examine the signal transduction pathways in pituitary hormone secretion.

    Upon joining the NIAAA, Lindsey became responsible for the activities related to stress effects on alcoholism. He serves as the scientific representative for a consortium of investigators examining the impact of stress on anxiety and alcohol consumption and is the project officer for individual awards on stress-related investigations. As the lead for the NIAAA initiative on PTSD and alcoholism comorbidity, he coordinates with the Department of Defense and the VA to promote research into the overlapping mechanisms underlying stress response and alcohol dependence. Recently he led a trans-NIH working group to develop a funding opportunity announcement on a systems biology approach to identifying resilience factors.

    close
    View Bio
  • Theresa Frangiosa, MBA
    Theresa Frangiosa, MBA Board Secretary, Board of Directors
    Cohen Veterans Bioscience

    Theresa Frangiosa, MBA

    Board Secretary, Board of Directors
    Cohen Veterans Bioscience

    Theresa Frangiosa, MBA, held executive positions in the pharmaceutical industry over a 25-year career before establishing Frangiosa and Associates, LLC in 2013, where she serves as Principal and Chief Executive Officer. She received her MBA in pharmaceutical marketing from St. Joseph’s University. She is a dementia patient caregiver and has been active in the brain disorder advocacy community for several years. Theresa also serves on the Board of Living Beyond Breast Cancer.

    close
    View Bio
  • Magali Haas, MD, PhD, MSE
    Magali Haas, MD, PhD, MSE CEO and President
    Cohen Veterans Bioscience

    Magali Haas, MD, PhD, MSE

    CEO and President
    Cohen Veterans Bioscience

    Dr. Haas founded Orion Bionetworks in July 2012 and serves as its CEO and President. Orion Bionetworks was transformed to Cohen Veterans Bioscience in 2015 to specifically dedicate research to improving the detection and treatment of post-traumatic stress (PTS) and traumatic brain injury (TBI) and related co-morbidities so that the burden of these conditions may be lessened on service members, veterans, and their families.

    Magali has over 15 years of pharmaceutical executive and clinical research experience, predominantly at Johnson & Johnson, where she assumed broad end-to-end development leadership roles in medical marketing, full clinical development, early development, and translational and biomarker sciences in psychiatry and neurology. She successfully filed NDAs in the US and Europe for risperidone indications in Autism, Adolescent Schizophrenia, Juvenile Bipolar Disorder and Conduct Disorders. She also led Development Teams evaluating compounds for Depression, Neuropathic Pain, Epilepsy, and Migraine Disorder.

    She served 3 years as Chief Science and Technology Officer for One Mind for Research, a nonprofit organization launched in May 2012 by Patrick J Kennedy. She orchestrated the launch of One Mind’s seminal programs, Apollo, an informatics research portal and, Gemini, an international TBI/PTSD research program.

    As an “intrapreneur” at J&J she established the first Neuroscience Translational Medicine & Integrative Solutions department, and co-founded the first Companion Diagnostics Center of Excellence as well as J&J’s Healthcare Innovation team. She serves on several advisory boards including Brain Canada, Prophase, Pear Therapeutics, PAASP and IMEC for nanoelectronics.

    Magali earned her BS in bioengineering from the University of Pennsylvania, an MS in biomedical engineering from Rutgers University, New Jersey, and her MD PhD with distinction in neuroscience from Albert Einstein College of Medicine, New York.

    close
    View Bio
  • Dallas Hack, MD
    Dallas Hack, MD Strategic Advisory Council
    Cohen Veterans Bioscience

    Colonel Dallas Hack, MD

    Strategic Advisory Council
    Cohen Veterans Bioscience

    Col(R) Dallas Hack, MD, served as the Director of the US Army Combat Casualty Care Research Program and Chair of the Joint Program Committee for Combat Casualty Care from 2008 to 2014 and as the Senior Medical Advisor to the Principal Assistant for Research and Technology, US Army Medical Research and Materiel Command from 2014 to 2015. He coordinated more than 70% of the Department of Defense (DoD) research to improve trauma care of those injured in combat. During this time, the DoD funded more traumatic brain injury research than any organization because of the increasing awareness of its massive burden in the military. Dallas has held numerous military medical leadership positions including Chief of Clinical Services at Fort Knox, KY, Commander of the NATO Headquarters Healthcare Facility, and Command Surgeon at the strategic level during Operations Enduring Freedom and Iraqi Freedom. He received numerous military awards including the Bronze Star, two Legion of Merit awards, and seven Meritorious Service Medals and was inducted as a Distinguished Member of the Military Order of Medical Merit. He has a BA from Andrews University, a MPH from Johns Hopkins University, a MD from Loma Linda University, a MSS from the US Army War College, and a CPE from the Certifying Commission in Medical Management. He was recognized as the Distinguished Alumnus of the Year by Loma Linda University in May 2015. After retiring from military service, Dallas has consulted with numerous organizations to advance research in brain health and improve clinical practice.

    close
    View Bio
  • Larry W. Hardy, PhD
    Larry W. Hardy, PhD Director of Pharmacology in the Discovery & Preclinical Research Group
    Sunovion Pharmaceuticals

    Larry W. Hardy, PhD

    Director of Pharmacology in the Discovery & Preclinical Research Group
    Sunovion Pharmaceuticals

    Larry W. Hardy, PhD, is director of pharmacology in the Discovery & Preclinical Research group at Sunovion Pharmaceuticals Inc. He has worked in R&D at Sunovion’s corporate headquarters in Marlborough, Massachusetts, for the past decade. Educated and trained in chemistry, biochemistry, and biophysics at MIT, UC Berkeley, and UCSF, Larry was a faculty member in pharmacology and molecular medicine at the University of Massachusetts Graduate School of Biomedical Sciences before his transition from academia to industry in 1997. His work focuses on discovery of novel therapies for neuropsychiatric diseases, and his contributions have ranged from early projects initiation, to computationally designed polypharmacology, to the guidance of clinical phase 1B pharmacodynamics studies. Currently he utilizes in vivo phenotypic assays and neurocircuitry analysis approaches, as an active participant in the Sunovion-Psychogenics collaboration, to optimize and understand possible clinical utilities of CNS-active small molecules. Larry is an internal champion for a novel compound, which these preclinical approaches suggest has potential as a new drug to treat disorders resulting from chronic and severe stress, including PTSD.

    close
    View Bio
  • Anthony Hassan, EdD, LCSW
    Anthony Hassan, EdD, LCSW CEO and President
    Cohen Veterans Network

    Anthony Hassan, EdD, LCSW

    CEO and President
    Cohen Veterans Network

    As the CEO and President of the Cohen Veterans Network, Dr. Anthony M. Hassan oversees the establishment of 25 mental health clinics nationwide. These clinics are designed to improve the mental health outcomes for post-9/11 veterans and their families, with a particular emphasis on post-traumatic stress, through high-quality, free, and accessible mental health care. In addition, he leads efforts to advance the field through funded research initiatives and training programs to improve care within the network and beyond.

    Hassan is a veteran, of enlisted rank in the United States Army and an Air Force officer, with 30 years of experience in military behavioral health, serving as a military social work officer, leader, clinician, and academic. He served during Operation Iraqi Freedom in 2004 on the first-ever Air Force combat stress control and prevention team embedded with the Army. He also led the largest military substance abuse and family advocacy programs in the Pacific. These programs were recognized as benchmark programs and training sites for all other Pacific bases.

    He most recently served as the inaugural Director and Clinical Professor of the Center for Innovation and Research on Veterans & Military Families (CIR) at the University of Southern California School of Social Work. During his tenure at CIR from 2009 to 2015, Hassan was instrumental in the exponential growth of the school’s military social work program and community-based research on veterans and military families. He has strong relationships with the most senior levels of leadership in the U.S. Department of Defense, U.S. Department of Veterans Affairs, and Washington, D.C.

    close
    View Bio

  • Douglas Haynes, MBA
    Douglas Haynes, MBA President
    Point72 Asset Management

    Douglas Haynes, MBA

    President
    Point72 Asset Management

    Doug Haynes is the President of Point72 Asset Management, L.P., originally joining the firm as Managing Director of Human Capital in February 2014. Prior to joining Point72, he was a Director at McKinsey & Company. Before joining McKinsey in 1992, he worked for the Central Intelligence Agency and then General Electric’s advanced materials business, which is now part of Sabic International. He earned a BS summa cum laude in mechanical engineering from West Virginia University, and received his MBA at the University of Virginia’s Darden Graduate Business School, where he was a Shermet Scholar.

    Doug is an active community member, dedicating a significant portion of his efforts to supporting Veterans’ initiatives. In addition to serving on the Board of the Robin Hood Foundation, Mr. Haynes helped launch its Veterans Advisory Board, which raised over $12 million to support the increase in veterans returning from Iraq and Afghanistan, and also works with New York-based companies to create more job opportunities for veterans. He serves on the Corporate Advisory Board of the Darden Graduate School of Business, the Board of the Canterbury School, SingTel’s Technology Advisory Board, and the Board of the Center for Global Enterprise.

    close
    View Bio
  • Stuart W. Hoffman, PhD
    Stuart W. Hoffman, PhD Scientific Program Manager, Senior Scientific Advisor for Brain Injury
    United States Department of Veteran Affairs

    Stuart W. Hoffman, PhD

    Scientific Program Manager, Senior Scientific Advisor for Brain Injury
    United States Department of Veteran Affairs

    Stuart W. Hoffman, PhD, is the Scientific Program Manager of the Brain Injury Portfolio in the Rehabilitation Research and Development Service and Senior Scientific Advisor for Brain Injury in the Office of Research and Development (ORD), US Department of Veteran Affairs. He is the point of contact for VA/ORD on traumatic brain injury research. In this role, Stuart has oversight for two VA TBI Research Centers and is the Co-chair of the Government Steering Committee for the VA/DoD Chronic Effects of Neurotrauma Consortium, as well as a VA TBI subject matter expert for the National Research Action Plan for Improving Access to Mental Health Services for Veterans, Service Members, and Military Families. He also serves on several intra- and interagency advisory committees for the VA and DoD, including the Congressionally-mandated Traumatic Brain injury Advisory Committee for the Veterans Health Administration. In addition, he is the VA representative on the Institute of Medicine’s Forum on Neuroscience and Nervous System Disorders. Stuart received his doctoral degree in behavioral and molecular neuroscience at Rutgers University in 1995 and completed his postdoctoral training in pharmacology at Virginia Commonwealth University in 1997. He has more than 30 years of translational neuroscience research experience focusing on neuroprotection and methods to promote recovery of function after brain injury.

    close
    View Bio
  • Martin Hofmann-Apitius, PhD
    Martin Hofmann-Apitius, PhD Professor of Applied Life Science Informatics
    Bonn-Aachen International Center for Information Technology

    Martin Hofmann-Apitius, PhD

    Professor of Applied Life Science Informatics
    Bonn-Aachen International Center for Information Technology

    Martin Hofmann-Apitius, PhD (molecular biology), is a Professor of Applied Life Science Informatics at Bonn-Aachen International Center for Information Technology (B-IT). The screening for novel genes involved in tumor metastasis led Martin into the area of functional genomics and subsequently to applied bioinformatics. Since 2002, he has been head of the Department of Bioinformatics at the Fraunhofer Institute for Algorithms and Scientific Computing (SCAI) in Sankt Augustin (Germany), a governmental non-profit research institute. The research activities of this department include automated methods for the extraction of relevant information from unstructured information sources such as journal publications, patents, and web-based sources; knowledge-based modeling of neurodegenerative diseases; mining in real-world data (social networks, patient forums, electronic patient records); and scalable solutions for unstructured information mining (high-performance computing, cloud computing). He has experience in both academic (University of Heidelberg (ZMBH), Forschungszentrum Karlsruhe (ITG), German Cancer Research Center (DKFZ) and industry (BASF, Boehringer Ingelheim, LION bioscience AG) research. Martin is the initiator and academic coordinator of the Innovative Medicines Initiative (IMI) project AETIONOMY.

    close
    View Bio
  • Andreas Jeromin, PhD
    Andreas Jeromin, PhD Consulting Biomarkers Director
    Cohen Veterans Bioscience

    Andreas Jeromin, PhD

    Consulting Biomarkers Director
    Cohen Veterans Bioscience

    Andreas Jeromin, PhD, is the founder and chief science officer of Atlantic Biomarkers, LLC, and joined Quanterix, Inc., as a scientific and medical advisor in 2014. He has established research programs in translational neuroscience in both industry and biotech for the last 15 years and co-authored more than 100 publications. He has also been elected a member of the Dana Alliance for Brain Initiatives. Andreas has led biomarker qualification programs in diagnostics and therapeutics in acute neurological injury and neurodegeneration in roles with increased responsibilities. These included several drug development programs from proof-of-concepts to a National Institute of Neurological Disorders and Stroke (NINDS)-supported phase III trial (Protect III). He also supports, as member of the scientific advisory board or steering committee, several biomarker qualification efforts such as the Alzheimer’s Disease Neuroimaging Initiative, the Coalition Against Major Diseases directed by the Critical Path Institute, the Alzheimer’s Association Cerebrospinal Fluid Quality Control Program, and biomarker assay standardization initiatives in other CNS disorders, including multiple sclerosis (Accelerated Cure), ALS, and Parkinson’s disease.

    close
    View Bio
  • Patricia Kabitzke, PhD
    Patricia Kabitzke, PhD Senior Scientific Program Manager
    Cohen Veterans Bioscience

    Patricia Kabitzke, PhD

    Senior Scientific Program Manager
    Cohen Veterans Bioscience

    Patricia Kabitzke is a behavioral neuroscientist, working on preclinical models of neuropsychiatric and developmental diseases such as PTSD, schizophrenia, and autism spectrum disorder. She has worked collaboratively with scientists across academia, biotech, big pharma, and nonprofit organizations, contributing expertise in study design, assay development, analysis, and offering creative solutions to complex problems. Dr. Kabitzke trained in the Department of Psychiatry at Columbia University with Dr. Christoph Wiedenmayer and was a Postdoctoral Research Fellow in Developmental Neuroscience and Behavior with Dr. Peter Balsam. More recently, she spearheaded and managed the Developmental Disorders group at PsychoGenics under the tutelage of Dr. Daniela Brunner. In addition to her research, Dr. Kabitzke is an Associate Editor for the International Journal of Comparative Psychology and is committed to the education and mentorship of future scientists, particularly women and underrepresented minorities.

    close
    View Bio
  • Eric R. Kandel, MD
    Eric R. Kandel, MD Nobel Laureate & University Professor
    Columbia University

    Eric R. Kandel, MD

    Nobel Laureate & University Professor
    Columbia University

    Eric R. Kandel, MD, is a Professor at Columbia University; Kavli Professor and Director at the Kavli Institute for Brain Science; Co-Director at the Mortimer B. Zuckerman Mind Brain Behavior Institute; and an Investigator at the Howard Hughes Medical Institute. A graduate of Harvard College and NYU School of Medicine, Kandel trained in neurobiology at the NIH and in psychiatry at Harvard Medical School. He joined the faculty of the College of Physicians and Surgeons at Columbia University in 1974 as the founding director of the Center for Neurobiology and Behavior. At Columbia, Eric organized the neuroscience curriculum. He is an editor of Principles of Neural Science, the standard textbook in the field now in its 5th edition.

    Eric’s research has been concerned with the molecular mechanisms of memory storage in Aplysia and mice. More recently, he has studied animal models in mice, age-related memory disorders, post-traumatic stress disorders, and nicotine, alcohol, marijuana, and cocaine addiction.

    Eric has received 23 honorary degrees, is a member of the US National Academy of Sciences as well as being a Foreign Member of the Royal Society of London and a member of the National Science Academies of Austria, France, Germany and Greece. He has been recognized with the Albert Lasker Award, the Heineken Award of the Netherlands, the Gairdner Award of Canada, the Harvey Prize and the Wolf Prize of Israel, the National Medal of Science USA, and the Nobel Prize for Physiology or Medicine in 2000.

    close
    View Bio
  • Dave King, BS
    Dave King, BS Founder
    Exaptive

    Dave King, BS

    Founder
    Exaptive

    Dave King has over 15 years of experience with technology startups and software development, in a wide range of capacities. After graduating from MIT with an electrical engineering/computer science degree, Mr. King helped to pioneer paperless manufacturing information systems in the electronics industry, which were recognized as best-in-class by industry leaders. He then focused on designing extensible software systems for ad-hoc visualization and analysis of large-scale multi-dimensional datasets. In 2011, he saw the need for a more modular and cross-disciplinary approach to data science, and founded Exaptive, Inc. in order to pursue ways that data and community can be combined to facilitate innovation. Exaptive was recently recognized by Gartner as a 2015 Cool Vendor.

    close
    View Bio
  • Karestan Chase Koenen, PhD
    Karestan Chase Koenen, PhD Professor of Psychiatric Epidemiology
    Harvard University

    Karestan Chase Koenen, PhD

    Professor of Psychiatric Epidemiology
    Harvard University

    Karestan Chase Koenen, PhD, researches and teaches about trauma and post-traumatic stress disorder (PTSD) at the Harvard TH Chan School of Public Health.

    The goal of her work is three-fold. First, she studies why, when exposed to similar traumatic events, some persons develop PTSD while others are resilient. She is interested in how genes shape risk for PTSD. This work is done through her leadership of the PTSD working group of the Psychiatric Genomics Consortium. Second, she investigates how trauma and PTSD influence weight gain and alter long-term physical health. Her work provides further evidence that PTSD is not solely a mental health problem, demonstrating that patients need access to integrated mental and physical health care. Third, she documents the global burden of trauma and PTSD through her work with the World Mental Health Survey Initiative. This work aims to advance the genetic analysis of serious mental illness while contributing to global mental health equity to countries that have been under-represented in neuropsychiatric genetics research.

    Karestan also advocates for victims of sexual violence. In May 2011, she testified before the House Foreign Affairs Full Committee hearing “Peace Corps at 50” about the epidemic of sexual violence and the victim blaming culture of the Peace Corps.

    close
    View Bio
  • Kenneth S. Kosik, MD
    Kenneth S. Kosik, MD Harriman Professor and Co-Director of the Neuroscience Research Institute
    University of California, Santa Barbara

    Kenneth S. Kosik, MD

    Harriman Professor and Co-Director of the Neuroscience Research Institute
    University of California, Santa Barbara

    Kenneth S. Kosik, MD, served as professor at the Harvard Medical School from 1996 until 2004 when he became the Harriman Professor and Co-Director of the Neuroscience Research Institute at the University of California, Santa Barbara. He was one of several scientists who discovered Tau protein in the Alzheimer tangles. He co-directs the Tau Consortium and co-founded the Learning and the Brain Conference. He received a Whitaker Health Sciences Award from MIT, a Milton Foundation Award from the Harvard Medical School, the Moore Award from American Association of Neuropathologists, the Metropolitan Life Award, the Derek Denny-Brown Award from the American Neurological Association, the Zenith and Temple Awards from the Alzheimer’s Association, the Ranwell Caputo Medal from the Argentine Society of Neurochemistry, the NASA Group Achievement Award to Neurolab Team, the Premio Aventis from the Academia Nacional de Medicina, Colombia, and the Santa Barbara Innovation Star Award. Kenneth co-authored The Alzheimer’s Solution: How Today’s Care is Failing Millions and How We Can Do Better and Outsmarting Alzheimer’s. His work, including the characterization in Colombia of the largest family in the world with familial Alzheimer’s, has appeared in the New York Times, the Wall Street Journal, the New Yorker, and on BBC, CNN and PBS.

    close
    View Bio

  • John H. Krystal, MD
    John H. Krystal, MD Robert L. McNeil, Jr., Professor of Translational Research, Chair of the Department of Psychiatry and Professor of Neuroscience
    Yale University School of Medicine

    John H. Krystal, MD

    Robert L. McNeil, Jr., Professor of Translational Research, Chair of the Department of Psychiatry and Professor of Neuroscience
    Yale University School of Medicine

    John H. Krystal, MD, is the Robert L. McNeil, Jr., Professor of Translational Research, Chair of the Department of Psychiatry and Professor of Neuroscience at the Yale University School of Medicine, and Chief of Behavioral Health Services at Yale-New Haven Hospital. He is a graduate of the University of Chicago, Yale University School of Medicine, and the Yale Psychiatry Residency Training Program. He has published extensively on the neurobiology and treatment of PTSD, depression, alcoholism, and schizophrenia. Notably, he led the discovery of the rapid antidepressant effects of ketamine in humans. He is the Director of Clinical Neuroscience Division of the VA National Center for PTSD, Executive Committee Member for the VA/DOD Consortium to Alleviate PTSD, and Director of the National Institute on Alcohol Abuse and Alcoholism (NIAAA) Center for the Translational Neuroscience of Alcoholism. John is a member of the US National Academy of Medicine. He served on the International Society for Traumatic Stress Studies Board of Directors (1988-1991), the NIAAA National Alcohol Advisory Council (2008-2012), and as president of the American College of Neuropsychopharmacology (2012). Currently, he is president of the International College of Neuropsychopharmacology, a member of the NIMH Mental Health Advisory Council, and editor of Biological Psychiatry.

    close
    View Bio
  • Emer Leahy, PhD
    Emer Leahy, PhD CEO
    PsychoGenics

    Emer Leahy, PhD

    CEO
    PsychoGenics

    Emer Leahy, PhD, is CEO of PsychoGenics Inc., a profitable preclinical CNS service company, CEO of PGI Drug Discovery LLC, a company engaged in psychiatric drug discovery with three partnered phase II clinical programs, and Adjunct Associate Professor of Neuroscience at Mount Sinai School of Medicine. She received her PhD in neuropharmacology from University College Dublin, Ireland, and her MBA from Columbia University. Emer has more than 25 years of experience in drug discovery, clinical development, and business development for pharmaceutical and biotechnology companies, including extensive knowledge of technology assessment, licensing, mergers and acquisitions, and strategic planning. Prior to her appointment as CEO of PsychoGenics, she was Vice President of Business Development, a position she also held at American Biogenetic Sciences and at AMBI Inc. She served on the Emerging Companies Section Governing Board for the Board of Directors of the Biotechnology Industry Organization, and currently serves on the Board of Directors of Intensity Therapeutics, the Business Review Board for the Alzheimer’s Drug Discovery Foundation, and the Scientific Advisory Board of the International Rett Syndrome Foundation.

    close
    View Bio
  • Israel Liberzon, MD
    Israel Liberzon, MD Professor of Psychiatry, Psychology, and Neuroscience
    University of Michigan

    Israel Liberzon, MD

    Professor of Psychiatry, Psychology, and Neuroscience
    University of Michigan

    Israel Liberzon, MD, is a Professor of Psychiatry, Psychology, and Neuroscience and Director of the Psychiatric Residency Research Track in the Department of Psychiatry at the University of Michigan. In 1992, he established the PTSD program at the University of Michigan and Ann Arbor VA Medical Center, a program that has since grown and remains on the forefront of biological research of PTSD worldwide. He also co-founded the Trauma, Stress, and Anxiety Research Group (TSARG) at the University of Michigan, which includes the Psychiatric Affective Neuroimaging Laboratory, a basic science (wet bench) laboratory, a MiRRR genetic repository, and a clinical research group.

    Israel’s primary research interest centers on emotions, stress, and stress-related disorders like PTSD, particularly in the regulation and dysregulation of stress response systems. His work integrates cognitive, functional neuroimaging, neuroendocrinological, and genetic approaches to studying stress, emotions, cognitive-emotion interactions, and the effects of emotions on decision making. Among his most unique contributions are the identification of contextual processing deficits in PTSD, the development of valid and widely used animal models for PTSD, and the collaborative work he co-leads for identifying genetic/genomic risk factors for PTSD.

    close
    View Bio
  • Sarah Hollingsworth Lisanby, MD
    Sarah Hollingsworth Lisanby, MD Director of Division of Translational Research
    National Institute of Mental Health

    Sarah Hollingsworth Lisanby, MD

    Director of Division of Translational Research
    National Institute of Mental Health (NIMH)

    Sarah Hollingsworth Lisanby, MD is the Director of Division of Translational Research at the National Institute of Mental Health (NIMH), where she oversees a research funding portfolio of approximately $400 million and helps set a national agenda for research on mental illness. She also works with Dr. Carlos Zarate and colleagues in the Division of Intramural Research Programs as Director of the Noninvasive Neuromodulation Unit (NNU), creating an important bridge between the Institute’s extramural and intramural research efforts.

    Sarah is one of the leading researchers in the area of neuromodulatory interventions for treating major depression, serving as a principal investigator on studies that range from basic research through clinical trials. Additionally, she is a prolific author with approximately 200 scientific articles and book chapters, and she has also received national and international recognition.

    Sarah’s prodigious research life has been matched by extensive service to NIMH and beyond. She has been a member of the NIMH Board of Scientific Counselors since 2013, and has chaired or been a member of a variety of NIH Study Sections since 2004. She also serves on the FDA Neurological Devices Advisory Panel, is on five editorial boards, and has held key leadership positions with numerous professional associations, including Chair of the American Psychiatric Association Task Force to Revise the Practice on Electroconvulsive Therapy.

    Hailing from Arlington, VA, Sarah received dual Bachelor of Science degrees in mathematics and psychology from Duke University in 1987, where she went on to receive an MD and complete a residency in psychiatry, serving as Chief Resident. In 1995 she joined Columbia University for a postdoctoral fellowship, and became an Assistant Professor in 1998. She was named Director of the Division for Brain Stimulation and Neuromodulation at Columbia University/New York State Psychiatric Institute in 2005, and Professor of Clinical Psychiatry at Columbia University in 2007, before returning to her alma mater as Chair for the Department of Psychiatry at Duke University in 2010, where she served for 5 years as tenured professor, department chair, and founding director of the Brain Stimulation & Neurophysiology Division.

    close
    View Bio
  • Brian L. Losey, Rear Admiral
    Brian L. Losey, Rear Admiral Commander of Naval Special Warfare Command
    United States Navy

    Brian L. Losey, Rear Admiral

    Commander of Naval Special Warfare Command
    United States Navy

    Brian Losey, Rear Admiral, is Commander of Naval Special Warfare Command in Coronado, California. He previously served as commander under the US Africa Command, Combined Joint Task Force Horn of Africa, and as commander, Special Operations Command Africa. His operational assignments have included a full range of duties in Sea, Air, Land (SEAL) Teams, SEAL Delivery Vehicle (SDV) Teams, and Special Boat Teams, and deployments to named and contingency operations around the world. He commanded SDV Team One and served as deputy commander and commander of the Naval Special Warfare Development Group. He has worked extensively with interagency and international partners in enhancing security cooperation relationships, capabilities, and capacities. Other assignments include duty as deputy commander, Naval Special Warfare Task Group, US 6th Fleet; Maritime Operations officer and deputy chief of Current Operations in the Joint Special Operations Command; and US 7th Fleet special warfare officer in USS Blue Ridge (LCC 19). He served in the executive office of the President as a director on the National Security Council Staff bridging two administrations. Brian holds a master’s degree in National Security Strategy from the National War College. He is a graduate of the Defense Language Institute, the Armed Forces Staff College, and Air Command and Staff College.

    close
    View Bio
  • Charles R. Marmar, MD
    Charles R. Marmar, MD Lucius N. Littauer Professor and Chair of the Department of Psychiatry
    New York University Langone Medical Center

    Charles Marmar, MD

    Lucius N. Littauer Professor and Chair of the Department of Psychiatry
    New York University Langone Medical Center

    Charles Marmar, MD, is the Lucius N. Littauer Professor and Chair of the Department of Psychiatry, New York University Langone Medical Center, and the Director of the Steven and Alexandra Cohen Veterans Center and Military Family Clinic. Previously, he was Professor and Vice Chair of the Department of Psychiatry at UCSF, and Associate Chief of Staff for Mental Health and Director of the PTSD Research Program at the San Francisco VA Medical Center. Charles graduated from the University of Manitoba with a BSc in 1966 and an MD in 1970, and did his residency in Psychiatry at the University of Toronto in 1976 and a psychiatry fellowship at the University of San Francisco in 1978.

    Internationally renowned for his expertise in PTSD for over 25 years, Charles’ focus ranges from combat-related conditions in veterans, including Iraq and Afghanistan veterans, to PTSD in refugees and earthquake victims. He has served on multiple committees and scientific advisory groups at the national level for both the VA and the National Institute of Mental Health and as counsel to the VA Medical Centers, fire departments, disaster response teams, and police departments, including the NYPD. An award-winning teacher and researcher, Charles is currently the principal investigator of numerous PTSD-related grants funded by the Department of Defense and private philanthropic organizations. He conducts studies in psychopharmacology, psychopathology, psychobiology, quality of care, psychotherapy treatment, and phenomenology of PTSD. He has served as president of several international societies, has published extensively, and is on the editorial board of several publications.

    close
    View Bio
  • Dennis McGurk, PhD
    Dennis McGurk, PhD Director of the Military Operational Medicine Research Program (MOMRP)
    United States Army

    Dennis McGurk, PhD

    Director of the Military Operational Medicine Research Program (MOMRP)
    United States Army

    Lt Colonel Dennis McGurk, PhD, is Director of the Military Operational Medicine Research Program (MOMRP), Ft Detrick, MD. The MOMRP is responsible for managing research to develop effective medical countermeasures against combat and operational stressors to maximize Service members’ health, readiness, and performance. He completed his PhD in experimental psychology from Texas Tech University in 2002. His first assignment as a research psychologist was at the Walter Reed Army Institute of Research (WRAIR). Dennis was the Senior Science Officer on the US Army Surgeon General’s Mental Health Advisory Team IIb (MHAT IIb) in Afghanistan, MHAT IV in Iraq, MHAT V in Afghanistan and was the Team Lead on the 2012 J-MHAT 8 in Afghanistan. In 2007, he assumed Command of the US Army Medical Research Unit-Europe. In 2010, he left Command and returned to WRAIR as the Chief of the Research Transition Office until 2013. Dennis has published in numerous peer-reviewed journals, was the lead author on two book chapters and has presented to numerous scientific and military conferences as well as to many senior military leaders including the Under Secretary of Defense for Personnel and Readiness, the Secretary of the Army, and the Secretary of the Navy. His military awards include the Meritorious Service Medal, the Army Commendation Medal, the Joint Achievement Medal, the Army Achievement Medal, the Humanitarian Service Medal, the Armed Forces Expeditionary Medal, the NATO Kosovo Medal, the Kosovo Campaign Medal, the Afghanistan Campaign Medal, the Iraq Campaign Medal, the Global War on Terrorism Medal, the Overseas Ribbon, the Air Assault Badge, and the Airborne Badge.

    close
    View Bio
  • Allison Provost, PhD
    Allison Provost, PhD Scientific Program Manager
    Cohen Veterans Bioscience

    Allison Provost, PhD

    Scientific Program Manager
    Cohen Veterans Bioscience

    Allison Provost, PhD, is a Scientific Program Manager who oversees Cohen Veterans Bioscience Biomarkers and Bioinformatics Programs. She previously led initiatives on biomarkers of neurodegeneration and worked on projects in computational modeling of Multiple Sclerosis. She received a PhD in Neuroscience from Harvard University where she was a National Science Foundation Graduate Fellow and Sackler Fellow in Psychobiology. In her research, she used optogenetics and live brain imaging to elucidate a deeper understanding of neuromodulation in healthy brains and understand the activity dependent nature of the formation of neural circuits. In addition to research, Allison has devoted time to community projects such as volunteering in an AmeriCorps program that worked with homeless individuals in the San Francisco Bay Area and leading a mentoring program at Harvard that served hundreds of students and faculty.

    close
    View Bio
  • Kerry Ressler, MD, PhD
    Kerry Ressler, MD, PhD Professor of Psychiatry
    Harvard Medical School

    Kerry J. Ressler, MD, PhD

    Professor of Psychiatry
    Harvard Medical School

    Kerry J. Ressler, MD, PhD, is Professor of Psychiatry at the Harvard Medical School and the James and Patricia Poitras Chair in Psychiatry, Chief Scientific Officer, and Chief of the Division of Depression and Anxiety Disorders at McLean Hospital. He began this role in August, 2015, after serving at Emory University in Atlanta for 18 years. He is also the 2016 President-Elect of the US Society for Biological Psychiatry. He received his Bachelor of Science degree in molecular biology from MIT, and his MD/PhD from Harvard Medical School.

    In 1992 at Harvard, Kerry was the first student of Dr. Linda Buck (Nobel Prize, 2004), helping to identify the molecular organization of the olfactory receptor system. Dr. Ressler is a previous Investigator of the Howard Hughes Medical Institute and a current member of the National Academy of Medicine (formerly the IOM). His work focuses on translational research bridging molecular neurobiology in animal models with human genetic research on emotion, particularly fear and anxiety disorders. He has published over 250 manuscripts ranging from basic molecular mechanisms of fear processing to understanding how emotion is encoded in a region of the brain called the amygdala, in both animal models and human patients.

    close
    View Bio
  • Adam Rosenberg, JD
    Adam Rosenberg, JD President and CEO
    Rodin Therapeutics

    Adam Rosenberg, JD

    President and CEO
    Rodin Therapeutics

    Adam Rosenberg is President and Chief Executive Officer of Rodin Therapeutics. He also serves as co-founder, Director and Chief Executive Officer at Teleos Therapeutics, a biotechnology company leveraging unique insights in zebrafish chemical biology and novel high-throughput screening technologies to discover new treatments for central nervous system disorders. Adam co-founded and served on the Board of Directors of Clean Membranes, a materials company based on MIT technology, and since 2009, has advised or served in interim executive roles with numerous companies in the healthcare and biotechnology sectors, including leading the digital health strategy for Brightstar (acquired by SoftBank) and serving on the advisory board of Gecko Health Innovations (acquired by Teva Pharmaceuticals). From 2005 to 2009, he co-founded and served as CEO of Link Medicine Corporation, a company focused on developing novel disease-modifying neurodegenerative treatments. He also advised the production of A Late Quartet, a feature film starring Christopher Walken, Philip Seymour Hoffman, and Catherine Keener, centered on a cellist in a world-class string quartet who is diagnosed with Parkinson’s disease. Adam holds a BA from Whittier College and a JD from the University of Virginia School of Law.

    close
    View Bio
  • Josef I. Ruzek, PhD
    Josef I. Ruzek, PhD Director of the Dissemination and Training Division of the National Center for Posttraumatic Stress Disorder
    VA Palo Alto Health Care System

    Josef I. Ruzek, PhD

    Director of the Dissemination and Training Division of the National Center for Posttraumatic Stress Disorder
    VA Palo Alto Health Care System

    Professor of Psychiatry and Behavioral Sciences
    Stanford University

    Josef I. Ruzek, PhD, is Director of the Dissemination and Training Division of the National Center for Posttraumatic Stress Disorder in the VA Palo Alto Health Care System. He is a Professor in the Department of Psychiatry and Behavioral Sciences at Stanford University and a co-editor of two editions of Cognitive-Behavioral Therapies for Trauma, and of Caring for Veterans With Deployment-Related Stress Disorders: Iraq, Afghanistan, and Beyond, published by the American Psychological Association. Joe is a member of the team that developed the joint Veterans Affairs–Department of Defense Clinical Practice Guidelines for Management of Traumatic Stress, and has been a lead for the national implementation of prolonged exposure evidence-based PTSD treatment within the Veterans Health Administration. In recent years, he has been working to develop and evaluate technology interventions for prevention and treatment of PTSD, including afterdeployment.org, a Congressionally-mandated site for returning veterans and their families, and PTSD Coach, an educational smartphone app designed to assist individuals with PTSD in managing their acute distress.

    close
    View Bio
  • Jeff Sabados, MBA, MPP
    Jeff Sabados, MBA, MPP CEO and co-founder
    Resilience Therapeutics

    Jeff Sabados, MBA, MPP

    CEO and co-founder
    Resilience Therapeutics

    Jeff Sabados, MBA, MPP, is an experienced entrepreneur and leader having co-founded Resilience Therapeutics in June 2014. Resilience, located in Boston, MA, is dedicated to assembling the best biotech scientists and research organizations in the world who will leverage precision medicine and our drug platform in order to make available new, disease-modifying therapeutics for veterans suffering from PTSD. Prior to Resilience, Jeff co-founded two successful companies – one out of Stanford University and one out of MIT – that are commercializing disruptive technologies.

    In the military, Jeff completed six deployments over 8 years both as a Surface Warfare Officer and US Navy SEAL. His deployments in Naval Special Warfare included one tour supporting Task Force K-Bar in Afghanistan, one tour leading several successful National-level SEAL Delivery Vehicle missions as both Platoon Commander and Task Unit Commander and a final tour as a Task Unit Commander where he led and had overall responsibility for 75 special operations personnel in South America.

    Jeff graduated from the MIT Sloan School of Management where he was awarded the Patrick J. McGovern Entrepreneur Award and the Martin Trust Fellow Award. Prior to MIT, he graduated from Harvard University with a Masters in Public Policy.

    close
    View Bio
  • Justin C. Sanchez, PhD
    Justin C. Sanchez, PhD Director of Biological Technologies Office
    Defense Advanced Research Projects Agency (DARPA), U.S. Department of Defense

    Justin C. Sanchez, PhD

    Director of Biological Technologies Office (BTO)
    Defense Advanced Research Projects Agency (DARPA), U.S. Department of Defense

    Justin Sanchez, PhD, is Director of Biological Technologies Office (BTO), Defense Advanced Research Projects Agency (DARPA). He joined DARPA as a Program Manager in 2013 to explore neurotechnology, brain science, and systems neurobiology. His research portfolio at DARPA includes unprecedented visualization and decoding of brain activity, new neuroprosthetic devices to help patients with memory deficits or neuropsychological illness, and advanced upper-limb prosthetic arm systems to restore movement and sensation that result from injury.

    Before coming to DARPA, Justin was an Associate Professor of Biomedical Engineering and Neuroscience at the University of Miami, and a faculty member of the Miami Project to Cure Paralysis. He directed the Neuroprosthetics Research Group, where he oversaw development of neural-interface medical treatments and neurotechnology for treating paralysis and stroke, and deep brain stimulation for movement disorders, Tourette’s syndrome and obsessive-compulsive disorder. Dr. Sanchez holds a PhD in biomedical engineering from the University of Florida.

    close
    View Bio
  • David J. Shulkin, MD
    David J. Shulkin, MD Secretary of Veterans Affairs
    United States Department of Veterans Affairs

    David J. Shulkin, MD

    Secretary of Veterans Affairs
    United States Department of Veterans Affairs

    The Honorable Dr. David J. Shulkin was nominated by President Trump to serve as the ninth Secretary of Veterans Affairs (VA) and was confirmed by the United States Senate on February 13th, 2017.

    Prior to his confirmation as Secretary, Dr. Shulkin served as VA’s Under Secretary for Health for 18 months, leading the Nation’s largest integrated health care system, with over 1,700 sites of care serving nearly nine million Veterans.

    Before he began his service with VA, Dr. Shulkin held numerous chief executive roles at Morristown Medical Center, and the Atlantic Health System Accountable Care Organization. He also served as President and CEO of Beth Israel Medical Center in New York City.

    Dr. Shulkin has held numerous physician leadership roles including Chief Medical Officer of the University of Pennsylvania Health System, Temple University Hospital, and the Medical College of Pennsylvania Hospital. He has also held academic positions including Chairman of Medicine and Vice Dean at Drexel University School of Medicine. As an entrepreneur, Dr. Shulkin founded and served as Chairman and CEO of DoctorQuality, one of the first consumer-oriented sources of information on quality and safety in healthcare.

    A board-certified internist, Dr. Shulkin is also a fellow of the American College of Physicians. He received his medical degree from the Medical College of Pennsylvania, and he completed his internship at Yale University School of Medicine and a residency and fellowship in General Medicine at the University of Pittsburgh Presbyterian Medical Center. He also received advanced training in outcomes research and economics as a Robert Wood Johnson Foundation Clinical Scholar at the University of Pennsylvania.

    Dr. Shulkin has been named as one of the “50 Most Influential Physician Executives in the Country” by Modern Healthcare. He has also previously been named among the “One Hundred Most Influential People in American Healthcare.” He has been married to his wife, Dr. Merle Bari, for 29 years. They are the parents of two grown children.

    close
    View Bio
  • Michael Singer, PhD
    Michael Singer, PhD CEO
    BrainScope

    Michael Singer, PhD

    CEO
    BrainScope

    Michael Singer, PhD, is Chief Executive Officer of BrainScope, where he has been instrumental in guiding the company through development and clinical validation of a product to aid in the assessment of traumatic brain injury, while securing venture capital investment and government research funding through military contracts. Before joining BrainScope, Michael was President of Revolution Health Investments, where he managed its sale to Everyday Health. He was previously the Chief Financial Officer, Executive Vice President of Corporate Development, and a Board member for Data Critical, a Seattle-based venture-backed wireless healthcare informatics and medical device company. At Data Critical, he was responsible for facilitating the company’s IPO, overseeing all financial functions, managing acquisitions and partnerships and eventually led the sale of Data Critical to GE. He has also worked as an executive at Microsoft Corporation responsible for developing small business and healthcare strategies, and for a decade as a healthcare investment banker and M&A generalist for Wolfensohn & Co., Montgomery Securities, and Alex. Brown in New York and San Francisco. He started his career at Union Bank of Switzerland in Zurich. He received his PhD from the London School of Economics.

    close
    View Bio
  • Murray B. Stein, MD, MPH, FRCPC
    Murray B. Stein, MD, MPH, FRCPC Distinguished Professor of Psychiatry and Family Medicine & Public Health, Vice Chair for Clinical Research in Psychiatry
    University of California San Diego

    Murray B. Stein, MD, MPH, FRCPC

    Distinguished Professor of Psychiatry and Family Medicine & Public Health, Vice Chair for Clinical Research in Psychiatry
    University of California San Diego

    Murray B. Stein, MD, MPH, FRCPC, is Distinguished Professor of Psychiatry and Family Medicine & Public Health, and Vice Chair for Clinical Research in Psychiatry at the University of California San Diego. He is also a staff psychiatrist at the VA San Diego Healthcare System. He graduated from the University of Manitoba and completed his residency and post-residency fellowship at the University of Toronto and the National Institute of Mental Health in Bethesda, MD, USA. He subsequently completed a Master of Public Health degree at the Johns Hopkins University Bloomberg School of Public Health in Baltimore, MD. Murray’s research interests include the epidemiology, neurobiology, and treatment of anxiety and trauma- and stressor-related disorders especially social phobia, panic disorder, and post-traumatic stress disorder. He has written or co-written over 500 peer-reviewed scientific articles on these topics, including in journals such as Journal of the American Medical Association, The Lancet, American Journal of Psychiatry, and JAMA Psychiatry. He is a Fellow of the American College of Neuropsychopharmacology, Co-Editor-in-Chief for UpToDate in Psychiatry, and a Deputy Editor for the journal Biological Psychiatry.

    close
    View Bio
  • Lara Sullivan, MD, MBA
    Lara Sullivan, MD, MBA Vice President, Pfizer CURES, Pfizer Medical
    Pfizer

    Lara Sullivan, MD, MBA

    Vice President, Pfizer CURES, Pfizer Medical
    Pfizer

    Lara Sullivan, MD, MBA, is Vice President, Pfizer CURES, Pfizer Medical. As a Pfizer senior leader and member of the Pfizer Medical Leadership Team, Lara leads the recently established Pfizer CURES platform, which aims to bring together patient foundations, impact investors, and venture philanthropy with Pfizer assets that serve specific patient populations. These novel partnerships and alliances with financial, philanthropic, and public sector partners will extend the scientific and development innovation opportunities for a select number of quality assets in Pfizer’s portfolio that have the potential to offer significant benefits to patients. Lara joined Pfizer in 2011 as Vice President and Head of Worldwide R&D Strategy & Portfolio Solutions within the global R&D organization. Prior to joining Pfizer, Lara was an Associate Partner at McKinsey & Company in the Pharmaceutical and Medical Products practice serving both big pharma and biotech clients across a variety of strategic and operational issues, with a particular emphasis on R&D productivity. Lara holds an MD from the University of Pennsylvania, School of Medicine, an MBA from The Wharton School at the University of Pennsylvania, and a BA in comparative literature from Cornell University.

    close
    View Bio
  • Michael C. Sullivan, BA
    Michael C. Sullivan, BA Managing Director, Chief of Staff, and Head of External Affairs
    Point72 Asset Management

    Michael C. Sullivan, BA

    Managing Director, Chief of Staff, and Head of External Affairs
    Point72 Asset Management

    Michael C. Sullivan, BA, is a Managing Director, Chief of Staff, and the Head of External Affairs of Point72 Asset Management, LP. He joined the firm in 2007 after working as a senior aide to a United States Senator, focusing on telecom, technology, and finance issues. Before serving in the US Senate, he worked for a member of the US House of Representatives who sat on the Energy and Commerce Committee. He was the Director of Planning and Strategy for the United States Telecom Association before working on Capitol Hill.

    Michael received his Bachelor of Arts degree in communications and political science from Vanderbilt University. He serves on a number of boards of organizations in the New York area and is a member of the Executive Committee of StudentsFirstNY, a New York nonprofit organization advocating for educational reform in New York State. Mr. Sullivan sits on the Board of the NYU Cohen Veterans Center, which is focused on research and treatment of veterans with post-traumatic stress and traumatic brain injury, and ConnCAN, an education reform nonprofit based in Connecticut. He is a member of the National Council of the American Enterprise Institute.

    close
    View Bio
  • Lois Winsky, PhD
    Lois Winsky, PhD Branch Chief, Molecular, Cellular, and Genomic Neuroscience
    National Institute of Mental Health

    Lois Winsky, PhD

    Branch Chief, Molecular, Cellular, and Genomic Neuroscience
    National Institute of Mental Health (NIMH)

    Lois Winsky, PhD, is Chief of the Molecular, Cellular and Genomic Neuroscience Research Branch within the Division of Neuroscience and Basic Behavioral Science of the National Institute of Mental Health (NIMH) where she also oversees the Psychopharmacology Program. She is leading efforts to advance the development and evaluation of novel cross-species assays of brain circuit activity as a means to address translational gaps in treatment development for mental disorders.

    Lois participates on several cooperative agreement steering committees focused on early-phase drug discovery, translational assay evaluation, and development of patient-derived reprogrammed cells as platforms for both therapeutics and biomarker development for mental disorders. She serves on the Therapeutics for Rare & Neglected Diseases Advisory Group for the National Center for Advancing Translational Sciences as well as the Translational Neuropharmacology Task Force for the NIMH Intramural Research Program. Lois is recognized for her in-depth expertise in neuropharmacology, behavioral pharmacology, and basic neuroscience.

    close
    View Bio

  • Jonathan Woodson, MD
    Jonathan Woodson, MD Professor of Surgery at the School of Medicine; and Professor of Health Law, Policy and Management at the School of Public Health
    Boston University

    Jonathan Woodson, MD

    Lars Anderson Professor in Management and Professor of the Practice at the BU Questrom School of Business; Professor of Surgery at the School of Medicine; and Professor of Health Law, Policy and Management at the School of Public Health
    Boston University

    Jonathan Woodson, MD, is the Lars Anderson Professor in Management and Professor of the Practice at the BU Questrom School of Business; Professor of Surgery at the School of Medicine; and Professor of Health Law, Policy and Management at the School of Public Health.

    Dr. Woodson leads the creation of a university-wide Institute for Health System Innovation as Faculty Director. The Institute for Health System Innovation will focus on expanding health system research initiatives across Boston University, deepening connections between scholars, policy-makers and corporations, and advancing curricular activities at Questrom and across BU’s schools and colleges. The Institute will focus on bringing together world-class academic, regulatory and industry resources to address important national and global health care challenges.

    Dr. Woodson has served since 2010 as Assistant Secretary of Defense for Health Affairs in the United States Department of Defense. He was the principal advisor to the Secretary of Defense for all health and force health protection related issues and ensured the effective execution of the DoD medical mission. His organization provided and maintained medical readiness for the medical services including during military operations, those held in control of the military services and those entitled to Tricare.

    Prior to serving as Assistant Secretary of Defense, Dr. Woodson was Associate Dean for Diversity and Multicultural Affairs and Professor of Surgery at BUSM. He received his BS in Biomedical Science (magna cum Laude) from the City College of New York, his MD from New York University School of Medicine and a Master’s in Strategic Studies from the US Army War College. Dr. Woodson is a Brigadier General in the US Army Reserves.

    close
    View Bio

2016 Cohen Veterans Care Summit Press Room

Media Advisory

Summit to Address Veterans PTSD-TBI Research and Care 

More than 200 thought leaders representing academia, government agencies, the military, industry, and the nonprofit sector will gather on September 22nd and 23rd in Washington, DC to discuss the state of science and care delivery in PTSD and TBI and to map a path to a first generation of diagnostics, therapeutics, and cures. 

World-class brain health experts will share the latest research on biomarkers, diagnostics, translational models, genetics, biosensors, and mobile health (including wearable technologies) for PTSD and TBI. Speakers include representatives from the National Institutes of Health, FDA, VA, Department of Defense, U.S. Army, and leading academic institutions — including Columbia, Stanford, Harvard, and NYU. Navy Seals and veterans who have experienced PTSD will also be participating. 

It is a critical time for addressing the vast mental health needs of our nation’s veterans. An estimated 20 veterans per day are committing suicide and many more are living for a lifetime with the invisible wounds of war. What is missing from the national discussion of caring for veterans — and all who suffer from PTSD and TBI, which often co-exists with PTSD — is the need for scientific research on its biological mechanisms and that of related conditions. This will lead to the faster development of objective diagnostic tests and more effective treatments. 

The Cohen Veterans Care Summit is co-hosted by Cohen Veterans Bioscience and Cohen Veterans Network.

Please join us for this premier event. [Registration is required]

WHAT:

Cohen Veterans Care Summit

Joining Forces on the Road to Discovery:
Advancing the PTSD Research Agenda

WHERE:

Ronald Reagan Building
1300 Pennsylvania Avenue
Washington, DC

WHEN:

September 22nd and 23rd, 2016
(Welcoming remarks begin at 8:00 am)

CONTACT:

press@cohenbio.org

For more information about the program and speakers, please visit http://www.cohencaresummit.org. Follow #CohenCareSummit on twitter.

The event will also be live streamed online at CohenCareSummit.org.

About the Cohen Veterans Care Summit

The Summit is jointly hosted by Cohen Veterans Bioscience and Cohen Veterans Network, both leading national non-profit organizations funded by billionaire philanthropist, Steven A. Cohen to advance the state of Post Traumatic Stress (PTS) & Traumatic Brain Injury (TBI) care today and tomorrow.

This year’s inaugural meeting will focus on advancements in bioscience and precision medicine and will highlight opportunities for advancing the PTSD & TBI research roadmap through public-private partnerships.  World-class brain health experts will share the state-of-the-art in biomarkers, diagnostics, translational models, genetics, biosensors and mobile health for PTSD and TBI.  We will also discuss how research advancements can be rapidly translated to best-in-class care delivery.

Participants in this invitation-only event will include leaders from academia, Department of Defense, National Institutes of Health, Veterans Administration, foundations and industry.  The agenda includes panel discussions, scientific presentations, and plenty of time for networking with peers to promote innovative collaborations.

By Joining Forces with partners from all sectors, we can accelerate the Veterans Mental Health agenda for Veterans, Service members and all individuals affected by PTS & TBI.

Cohen Veterans Bioscience

Cohen Veterans Bioscience

Cohen Veterans Bioscience is the only 501(c)(3) non-profit research organization with a singular focus on PTSD and TBI research. We are dedicated to fast-tracking the development of diagnostic tests and personalized therapeutics for the millions of veterans and civilians who suffer the devastating effects of trauma on the brain. More information is available at www.cohenveteransbioscience.org

Cohen Veterans Network

Cohen Veterans Network

Cohen Veterans Network is a 501(c)(3) nonprofit foundation whose mission is to improve the quality of life for post-9/11 veterans and their families by focusing on improving mental health outcomes. The goal of the Cohen Veterans Network is to build a network of free or low-cost outpatient mental health clinics for veterans and their families in high-need communities, in which trained clinicians deliver holistic evidence-based care to treat mental health conditions, especially post-traumatic stress.

2016 Cohen Veterans Care Summit Sponsors:

cvb-sponsor-star-gold  Gold Sponsor:

Pfizer

cvb-sponsor-star-silver  Silver Sponsors:

Thomson Reuters

Sunovion Pharmaceuticals